HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

ORMP — Oramed Pharmaceuticals Inc.

ORMP (Oramed Pharmaceuticals Inc.) stock: $3.86, $160.6M market cap, $38.0M cash, $122.6M EV, $181.6M fully diluted market cap. Lead program: ORMD-0801 8 mg (Type 2 Diabetes Mellitus), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

We are a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we believe complement our long-term business objectives and technology focus.

Source: 10-K FY2025 via SEC EDGAR

Share price
$3.86
Market cap
$160.6M
Cash
$38.0M
Enterprise value
$122.6M

Balance sheet

Cash$38.0M
Debt$0.0M
Net cash$38.0M
Enterprise value$122.6M
Basic shares41.6M shares
Fully diluted shares47.0M shares
Fully diluted market cap$181.6M
Cash per share$0.91
Quarterly burn$0.2M
Cash runway189.8 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common
41.6M
Pre-funded warrants
0.0M
Options
1.5M
RSUs
3.9M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
47.0M

Cap table as of 2026-06-30.

Price history

Loading ORMP daily closes…

Loading price history…

Next catalyst

ORMD-0801 8 mg · Jun 6 - Jul 18 in 7 mo · Phase 3 · Type 2 Diabetes Mellitus

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego